title: Reinduction with the same cytostatic treatment in patients with metastatic breast cancer: an Eastern Cooperative Oncology Group study.
abstract: OBJECTIVE
  To investigate the therapeutic value of reinduction with the same cytostatic treatment that had been used in induction treatment for women with metastatic breast cancer.
  
  
  METHODS
  One hundred six women with metastatic breast cancer were given dibromodulcitol (mitolactol), doxorubicin, vincristine, tamoxifen, and fluoxymesterone (DAVTH) for 6 months of induction treatment, then randomized to receive one of two chemotherapy regimens if they had obtained an induction partial response (PR) or no change (NC), or to receive observation versus chemotherapy if they had obtained an induction complete response (CR). Patients were then retreated with DAVTH reinduction after relapse.
  
  
  RESULTS
  Seventy-four patients were eligible or had minor reasons for ineligibility. Severe or life-threatening toxicity was documented in 46%, and lethal toxicity in 4%. Eighteen percent had a response on reinduction (zero of 16 induction nonresponders, 15% induction PR, 44% induction CR). The median time to treatment failure (TTF) from reinduction was 3 months, and the median survival duration from reinduction was 14 months. In a logistic model, factors associated with more reinduction responses were observation after induction CR (P = .002) and age greater than 55 years (P = .04). Time since induction was not significant.
  
  
  CONCLUSIONS
  Reinduction of response after treatment failure remains a therapeutic problem. The need for better salvage treatment underlines the importance of developing new regimens.
authors.affiliation: Department of Medical Oncology, University of Pretoria, South Africa.
authors.forename: G
authors.initials: G
authors.lastname: Falkson
authors.forename: R
authors.initials: R
authors.lastname: Gelman
authors.forename: J
authors.initials: J
authors.lastname: Glick
authors.forename: C I
authors.initials: CI
authors.lastname: Falkson
authors.forename: J
authors.initials: J
authors.lastname: Harris
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005474:Fluoxymesterone / Q000008:administration & dosage; D006801:Humans; D016015:Logistic Models; D008875:Middle Aged; D008936:Mitolactol / Q000008:administration & dosage; D009362:Neoplasm Metastasis; D012074:Remission Induction; D016019:Survival Analysis; D013629:Tamoxifen / Q000008:administration & dosage; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D013629:Tamoxifen; D014750:Vincristine; D004317:Doxorubicin; D005474:Fluoxymesterone; D008936:Mitolactol